Article thumbnail

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies

By P Hamberg, N Steeghs, W J Loos, D van de Biessen, M den Hollander, M Tascilar, J Verweij, H Gelderblom and S Sleijfer
Topics: Clinical Studies
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2883699
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A 1024: 87–94
  2. (2009). A phase I study of sunitinib plus irinotecan in the treatment of patients with recurrent glioma. J Clin Oncol 27: e13024
  3. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368: 1329–1338 Deprimo SE,
  4. (1992). Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse.
  5. (2004). Quantitation of SU11248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatography with tandem mass spectrometry following semi-automated liquid-liquid extraction.
  6. (2010). Suppl 7: 283 5075 De Bruijn